Innoviva

Valuation Analysis

About the Company

Innoviva en bref

Innoviva (INVA) is currently trading at 19,63 € with a market capitalization of 1,4 Md €. The trailing P/E ratio stands at 3.59x, with a forward P/E of 10.18x. The 52-week range spans from 14,42 € to 21,95 €; the current price is 10.6% below the yearly high. Year-over-year revenue growth stands at +10.6%. The net profit margin stands at 119.88%.

💰 Dividende

Innoviva currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent Innoviva (INVA) au consensus : None. L'objectif de cours moyen est de 30,98 €, soit un potentiel de +57.85% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,71 € à 40,14 €.

Innoviva : la thèse d'investissement en détail

Innoviva (INVA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 74.1%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 50.72% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Short interest sits at 10.7% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.33, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.2x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The analyst consensus price target implies 57.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (10.7%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Innoviva?

Compare top-rated brokers — low fees, trusted providers, fully regulated.